Mini-reviewMicroenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance
Section snippets
General background
Hodgkin Lymphoma (HL) first involves lymph nodes [1]. It is characterized by a minority of tumor cells (less than 1% of the total cell population), collectively termed Hodgkin and Reed–Sternberg (HRS) cells, representing the small, mono-nucleated Hodgkin (H) cells and the large, binucleated or multi-nucleated Reed–Sternberg (RS) cells [2], [3] embedded in an inflammatory microenvironment.
HL has been divided into classical HL (cHL), which accounts for 95% of all cases, and the less frequent
cHL microenvironment composition
HRS cells represent about 1% of the tumor mass, but through efficient organization of the abundant surrounding immune cells, they are able to generate a highly aggressive and potentially lethal malignancy. The cHL microenvironment is composed by numerous small CD4-positive T cells and a variable number of eosinophils, histiocytes/macrophages, B-cells, mast cells, plasma cells, fibroblasts, mesenchymal stromal cells (MSCs) and endothelial cells (Fig. 1). HRS cells are often in close contact with
The Tumor-Hosts symbiosis in cHL microenvironment
The lack of the B-cell receptor (BcR) makes the low number of HRS cells susceptible to apoptosis, forcing them to survive by building a friendly/protective microenvironment unable to exert an effective immune response (Fig. 1, Fig. 2).
HRS cells apply several strategies to create their TME: i) recruitment (direct) of immune cells by cytokines/chemokines secreted by HRS cells or normal cells “educated” by tumor cells [33], [34] (Fig. 1); ii) modification of immune cells' phenotype (Fig. 2); iii)
Immune escape mechanisms
HRS cells have developed efficient immunosuppressive mechanisms to proliferate and survive for long periods. They live surrounded by immune cells “educated” to build an immune privileged niche that, instead of exerting anti-tumor effects, promotes the growth/survival of HRS cells. As a consequence, the activity, type, number and proportions of TME cells are now considered new prognostic factors as well as targets for new therapeutic approaches [60].
HRS cells employ different mechanisms to
Autocrine and TME-mediated proliferation and survival of HRS cells
Several pro-survival/proliferative signals determine the fate of HRS cells. The current hypothesis is that HRS cells can grow through the expression of cytokines and tyrosine kinase receptors (RTKs) and their corresponding ligands (autocrine mechanisms) or through the continuous stimulation by the extracellular matrix and by molecules secreted and/or surface expressed by TME cells (paracrine mechanisms). Also the constitutive activation of the NF-kB pathway in HRS cells may be due to autocrine
The impact of TME on drug response
Emerging data suggest that TME, by providing a protective niche, allows cancer cells to escape from the cytotoxic effects of chemotherapy and radiation [96], [97]. Indeed, drugs very active in vitro do not always get good results in vivo. An example is the proteasome inhibitor Bortezomib that exerted a potent anticancer activity in vitro against HRS cells but not in vivo when used as a single drug [98].
Given the role of TME in cHL, it is fundamental to discover what are the microenvironmental
Conclusion
Based on current knowledge, it is clear that HRS cells in symbiosis with “normal cells” build a tumor microenvironment where apparently all goes well: tumor grows if the TME grows; the TME grows if tumor cells survive; tumor cells survive if TME counteracts the cytotoxic effects of anticancer therapies and immunity.
However, there are a lot of open questions. For example, the role of immunosuppressive cells such as Tregs or M2-immunosuppressive monocytes is not so clear. Indeed, several authors
Conflict of interest
The authors have no competing interests.
Acknowledgments
The authors apologize to researchers whose work is not cited due to space limitations.
This work was supported by a grant from the Italian Association for Cancer Research (AIRC; grant no. IG 15844 to DA) and by Ministero della Salute, Ricerca Finalizzata FSN, I.R.C.C.S., Rome, Italy.
References (111)
- et al.
Lymphomagenesis in Hodgkin lymphoma
Semin. Cancer Biol
(2015) - et al.
Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma
Blood
(2012) - et al.
Microenvironment and HIV-related lymphomagenesis
Semin. Cancer Biol
(2015) - et al.
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
Blood
(2011) - et al.
The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component
Semin. Cancer Biol
(2014) - et al.
Spindle-shaped CD163+ rosetting macrophages replace CD4+ T-cells in HIV-related classical Hodgkin lymphoma
Mod. Pathol
(2013) - et al.
Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines
Blood
(1995) - et al.
Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells
Blood
(2013) - et al.
Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells
Am. J. Pathol
(2002) - et al.
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: evaluation based on data from 1450 patients
Mayo Clin. Proc
(2015)
The role of cytokines in classical Hodgkin lymphoma
Blood
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues
Ann. Oncol
High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma
Am. J. Pathol
Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells
Am. J. Pathol
Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells
Am. J. Pathol
Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils
Blood
PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma
Blood
Reed-Sternberg cell-derived lymphotoxin-alpha activates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma
Blood
Preclinical activity of the repurposed drug Auranofin in classical Hodgkin lymphoma
Blood
Outsmart tumor exosomes to steal the cancer initiating cell its niche
Semin. Cancer Biol
Insights in Hodgkin Lymphoma angiogenesis
Leuk. Res
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma
Leuk. Res
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
Blood
High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas
Blood
Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells
Immunol. Lett
PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
Blood
Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma
Blood
Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma
Blood
Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines
Blood
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL
Blood
Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha
Blood
Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival
Blood
Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease
Blood
The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1
Blood
Activated DDR1 increases RS cell survival
Blood
Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma
Blood
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival
Blood
Reed-Sternberg cells form by abscission failure in the presence of functional aurora B kinase
PLoS ONE
Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells
Proc. Natl. Acad. Sci. U.S.A.
Hodgkin lymphoma
J. Clin. Invest
Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma
Proc. Natl. Acad. Sci. U.S.A.
Modeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis
Int. J. Cancer
Current status of prognostication in classical Hodgkin lymphoma
Br. J. Haematol
The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment
Leuk. Lymphoma
Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions
Int. J. Cancer
Increased expression of CD4+CD25 +FOXP3+ regulatory T cells correlates with Epstein-Barr virus and has no impact on survival in patients with classical Hodgkin lymphoma in Brazil
Med. Oncol
Epstein-Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients
Br. J. Haematol
Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells
Leuk. Lymphoma
Angiogenesis and mast cells in Hodgkin lymphoma
Leukemia
The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma
Appl. Immunohistochem. Mol. Morphol
Cited by (77)
Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for Hodgkin's lymphoma patients
2023, Jornal de PediatriaCitation Excerpt :NLPHL is the rarest form of the disease, with approximately 5% of all cases of HL, while CHL affects most cases.5 When diagnosed, 80% of NLPHL cases present with early or localized disease (I or II) without B symptoms,6 whereas CHL mostly includes patients in the more advanced stages (III or IV), presence of B symptoms, associated with the presence of Epstein-Barr virus (EBV) and unfavorable prognosis.6,7 The determination of HL dissemination capacity is extremely important in the clinical management, treatment, and prognosis of the patient.3
FOXP3+/CD68+ ratio within the tumor microenvironment may serve as a potential prognostic factor in classical Hodgkin lymphoma
2022, Human ImmunologyCitation Excerpt :Classical Hodgkin lymphoma (CHL), a rare B-cell malignancy, consists of a minority of neoplastic Hodgkin Reed-Sternberg (HRS) cells embedded in abundant reactive inflammatory cells forming the tumor microenvironment (TME) [1,2].
Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma
2021, Cancer LettersCitation Excerpt :Furthermore, trabectedin inhibits angiogenesis through a direct effect on endothelial cells [15] and by reducing the secretion of vascular endothelial growth factor by tumor cells and TAMs [13]. These functions may enable this drug to combat tumors in which the TME plays an important role, including classic Hodgkin lymphoma (cHL) [16]. In cHL, a low number of malignant cells called Hodgkin Reed Sternberg (HRS) cells are surrounded by a protective TME [16].
Macrophages and angiogenesis in human lymphomas
2024, Clinical and Experimental Medicine